Clinical Trials Logo

Adult Solid Tumor clinical trials

View clinical trials related to Adult Solid Tumor.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06403436 Recruiting - Cancer Clinical Trials

A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors

TT-CSP-001
Start date: November 7, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to test the safety and therapeutic effect of TT125-802 (single agent) in subjects with advanced solid tumors.

NCT ID: NCT06059547 Recruiting - Bladder Cancer Clinical Trials

Neoadjuvant Immunotherapy in Combination With the Anti-GDF-15 Antibody Visugromab (CTL-002) for Treatment of Muscle Invasive Bladder Cancer

Start date: September 6, 2023
Phase: Phase 2
Study type: Interventional

This is a multi-center, stratified and single-blinded Phase 2 study of neoadjuvant immunotherapy in combination with the antiGDF15 antibody visugromab (CTL-002) for the treatment of subjects with MIBC set to undergo radical Cystectomy (RC) who cannot receive or refuse to receive cisplatin-based chemotherapy.

NCT ID: NCT05752552 Recruiting - Lung Cancer Clinical Trials

Study to Determine the Safety and Pharmacokinetics of DO-2 in Patients With Advanced or Refractory Solid Tumours

Start date: December 20, 2022
Phase: Phase 1
Study type: Interventional

This study is a first-in-human, open-label, 2-part, Phase 1 dose escalation study of DO-2, administered orally to patients with advanced or refractory solid tumours, with MET aberrations, and no available, approved therapeutic alternative.

NCT ID: NCT04705818 Recruiting - Clinical trials for Advanced Solid Tumor

Combining Epigenetic And Immune Therapy to Beat Cancer.

CAIRE
Start date: July 23, 2021
Phase: Phase 2
Study type: Interventional

Umbrella study structure to independently and simultaneously assess the effects of the association of durvalumab and tazemetostat in multiple solid tumors.

NCT ID: NCT03061305 Recruiting - Cancer Clinical Trials

Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors

Start date: November 2016
Phase:
Study type: Observational [Patient Registry]

Many patients are treated for advanced cancer without knowledge of underlying molecular features that might indicate FDA approved therapies or potential eligibility for biomarker-selected clinical trials. The Strata Trial (STR-001-001) has been initiated by Strata Oncology to evaluate the clinical benefit of systematic comprehensive genomic profiling for participants with advanced cancer using real-world data and endpoints, while assessing the proportion of participants available for clinical trials and approved targeted therapies in advanced and/or aggressive cancers. The Strata Trial uses surplus, or leftover, tumor specimens for molecular profiling and does not require additional study-specific procedures.